Stroke clinical trials at UCLH 

UCLH is a specialist centre for research in the ‘hyper-acute’ time period following a stroke (within 9 hours). We are able to offer our patients cutting-edge treatments such as; new promising drugs, new devices and other interventions such as thrombectomy (removing the clot from the cerebral blood vessels) and induced hypothermia (reducing body temperature).

We are closely partnered with UCL where there are several stroke research groups investigating prevention, rehabilitation and diagnosis (see links below).

Patients and relatives will be offered the opportunity to take part in research whilst on the stroke unit and in outpatients. We also have studies which patients can take part in after they have been discharged. If you would like to take part please contact us on the details below.

See below for our trials and studies. Please note that all trials have strict entry criteria so will not be suitable for everyone.

Clinical trials

PISTE
The primary objective of the trial is to determine if endovascular thrombectomy in addition to IV thrombolysis improves the proportion of patients with favourable functional 3 month outcome (defined by modified Rankin 0-1) in patients with acute ischaemic stroke due to occlusion of the middle cerebral or intracranial internal carotid artery.

ENCHANTED
This is an international randomised controlled trial to establish the effects of low–dose rtPA and the effects of early intensive blood pressure lowering in patients with acute ischaemic stroke Patient with a definite acute ischaemic stroke <4.5 hours, i.v. rtPA indicated and planned, and has a systolic BP ≤185 mmHg. 

TICH-2
Pragmatic phase III prospective double blind randomised controlled trial whether tranexamic acid is safe and reduces death and dependency after primary intracerebral haemorrhage (PICH). The results will determine whether tranexamic acid should be used to treat PICH, for which currently there is no effective therapy.

DIAS - 4
Randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of Desmoteplase in subjects with acute ischemic stroke. Patients must have vessel occlusion or high-grade stenosis on CTA in proximal cerebral arteries. (within 3-9 hrs from onset)

CLOTBUSTER
This is a randomized, placebo controlled, double-blind phase 3 clinical study to evaluate the efficacy and safety of Ultrasound (US) using the SonoLysis Headframe as an adjunctive therapy to tissue plasminogen activator (tPA) treatment in subjects with acute ischemic stroke.

WAKE UP
Efficacy and safety of MRI-based thrombolysis in wake-up stroke: a randomised, double-blind, placebo-controlled trial

PENUMBRA
The objective of this study is to determine the natural history of acute ischemic stroke from large vessel thromboembolism in the brain. The target population is a stroke cohort with a known infarct volume who presents within 8 hours from symptom onset with a NIH Stroke Scale (NIHSS) score >10.

STROKE INF
Cluster randomised trial investigating whether prophylactic use of antibiotics in dysphagic stroke patients will be better than the current practice in reducing chest infections and their consequences in stroke patients. (within 48 hrs from onset)

ECST-2
The 2nd European Carotid Surgery Trial. Uses a risk model based on clinical characteristics to calculate a 5-year Carotid Artery Risk (CAR) score, which stratifies patients as at high (risk 15% or more), intermediate (risk 7.5-15%), or low risk (<7.5%) of recurrent stroke at the time of randomisation.

Patients will be randomly allocated in equal proportions to be treated by 1) immediate carotid revascularisation with optimised medical therapy (OMT) or 2) OMT alone (in the latter arm, endarterectomy may be performed at a later stage if it becomes more clearly indicated).

VIST
Randomised trial comparing vertebral stenting vs. best medical treatment for patients with symptomatic vertebral stenosis (within 6 months from onset).

PRESERVE
Randomized trial to determine whether a strategy of intensive, versus standard, treatment of BP in hypertensive individuals with cerebral small vessel disease (SVD) and leukoaraiosis is associated with reduced cognitive decline. 

RESTART
For adults surviving spontaneous (non-traumatic intracerebral haemorrhage (ICH) who had taken an antithrombotic (i.e. anticoagulant or antiplatelet) drug for the prevention of vaso-occlusive disease before the ICH, does a policy of starting antiplatelet drugs result in a beneficial net reduction of all serious vascular events over at least two years compared with a policy of avoiding antiplatelet drugs?

Clinical studies

CROMIS 2
Clinical Relevance Of Microbleeds In Stroke - Intracerebral Haemorrhage. Microbleeds and genetic risk factors to predict the risk of intracranial haemorrhage in patients treated with anticoagulation following cardioembolic stroke due to atrial fibrillation.

PLORAS
Using structural and functional Magnetic Resonance Imaging, the study aims to learn how the brain recovers from stroke injury.

NeuroFAST
Post stroke fatigue (PSF) a major problem in stroke and is poorly understood. Clinical management is almost non-existent and this study aims to understand the basis of PSF.

NotFAST
Understanding the nature of the clinical problem and determining factors associated with fatigue in stroke patients without depression

HEARS
The aim of this study is to assess hearing in patients who have had a stroke in order to quantify and characterise their hearing needs, identify the appropriate rehabilitation and validate a hearing screening test that can be used in the stroke unit. 

 

 

 Contact details

Hyper-acute stroke unit (HASU)

Patient enquiries
Telephone: 020 3447 0784

GP enquiries
Telephone: 020 3447 0707/020 3447 0727
Fax: 020 3447 0793
Email: ucl-tr.uclhhasu@nhs.net

Other information
HASU Ward Sister - Roxana Moise
Telephone: 020 3447 0727
 

Service manager - Camelia Melody
Email: camelia.melody@uclh.nhs.uk